Meta-analysis primary and secondary outcome analyses for the two datasets using a weighted fixed effect model Fargen et al10
| Outcome measure | IA arm (n (%) unweighted) | Medical arm (n (%) unweighted) | OR (95% CI), p value |
|---|---|---|---|
| Included studies with LVO confirmed at time of randomization (dataset 1) | |||
| Primary outcome | |||
| mRS 0–2 at 90 days | 251 (38.3) | 136 (25.8) | 1.67 (1.29 to 2.16), p=0.0001 |
| Secondary outcomes | |||
| mRS 0–1 at 90 days | 156 (23.8) | 66 (12.5) | 1.93 (1.39 to 2.68), p<0.0001 |
| mRS 0–3 at 90 days | 348 (53.1) | 224 (42.4) | 1.46 (1.16 to 1.85), p=0.002 |
| Mortality at 90 days | 122 (18.6) | 114 (21.6) | 0.80 (0.60 to 1.07), p=0.13 |
| mRS shift analysis (mean) | 3.35 | 3.73 | p<0.0001 |
| All included studies (dataset 2) | |||
| Primary outcome | |||
| mRS 0–2 at 90 days | 419 (39.1) | 271 (32.6) | 1.27 (1.04 to 1.54), p=0.018 |
| Secondary outcomes | |||
| mRS 0–1 at 90 days | 270 (25.2) | 169 (20.3) | 1.22 (0.97 to 1.53), p=0.09 |
| mRS 0–3 at 90 days | 600 (56.0) | 412 (49.5) | 1.25 (1.04 to 1.51), p=0.019 |
| Mortality at 90 days | 203 (19.0) | 156 (18.8) | 0.96 (0.76 to 1.22), p=0.73 |
| mRS shift analysis (mean) | 3.16 | 3.42 | p=0.003 |
IA, intra-arterial; LVO, large vessel occlusion; mRS, modified Rankin score.